Drugs / ONO-2910
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04504760 | Jul 2020 → Mar 2021 | — | Ono Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06538272 | Aug 2023 → Sep 2024 | chemotherapy-induced neuropathy | Ono Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ONO-2910 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06538272 ↗ |
| Modality | Small molecule | — CHEMBL6068519 ↗ |
| Route | Oral | “administered orally” NCT04504760 ↗ |